| Chair | Jason P. Kirkness, PhD, ATSF | St Paul, MN |
| Vice Chair | Nina M. Patel, MD, BMedSci | New York, NY |
| Committee Member | Aryeh Fischer, MD | Denver, CO |
| Committee Member | Benjamin T. Suratt, MD | Charlestown, MA |
| Committee Member | Chantal Darquenne, PhD | La Jolla, CA |
| Committee Member - Immediate Past Chair | Courtney Crim, MD, ATSF | Raleigh, NC |
| Committee Member | Craig S. Conoscenti, MD, FCCP, ATSF | Seattle, WA |
| Committee Member | Heidi M. Mansour, PhD, RPh | Port St. Lucie, FL |
| Committee Member | Joshua P. Fessel, MD, PhD, ATSF | Bethesda, MD |
| Committee Member | Kathryn A. Hibbert, MD | Boston, MA |
| Committee Member | Lida P. Hariri, MD, PhD, ATSF | Boston, MA |
| Committee Member | Michael P. Coughlin, DO | North Olmsted, OH |
| Committee Member | Michelle Eakin, PhD | Baltimore, MD |
| Committee Member | Mudiaga Sowho, MD, MPH | Lawrenceville, NJ |
| Committee Member | Nadine Mokhallati, MD | Overland Park, KS |
| Committee Member | Neeraj Vij, MS, PhD, ATSF | Baltimore, MD |
| Committee Member | Nirupama Putcha, BA, MD | Baltimore, MD |
| Committee Member | Sean Agbor-Enoh, MD, PhD | Bethesda, MD |
| Committee Member | Sydney B. Montesi, MD | Boston, MA |
| Committee Member - PAR Representative | Teresa R. Barnes | St. Louis, MO |
| Committee Member | William A. Bulman, MD | Pelham Manor, NY |
| Committee Member | William A. Bulman | |
| Committee Member | Xavier Soler, MD, PhD | Sleepy Hollow, NY |
| Staff | Vlada K. O'Hara | New York, NY |
| Staff | Dayna Howell | New York, NY |
| Staff | Michelle Turenne, CAE | New York, NY |
This committee provides a forum within the Society that focuses on identifying and instilling principles of translational and clinical science specific to the discovery and development of new drugs and devices relevant to the American Thoracic Society mission. The committee takes a multifaceted and collaborative approach to supporting the development of innovative therapies for those with respiratory diseases, critical illness and sleep disorders. It will provide the Society with the strategies and specific methods to distribute knowledge surrounding the discovery and development of new drugs and devices, which relates to the art and principles of translational research to its members. Additionally, the committee will serve as an ad hoc resource to the ATS Committee on Ethics and Conflict of Interest Committee and the Steering Committee on Advancement and Learning (SCALe). The goal is to enhance collaboration among all scientists and advance all science, regardless of genesis or financial support.
Benchmarks, 2024-2025:
▪ Develop and implement educational and collaborative programs for the ATS International Conference, stand-alone content utilizing webinars and podcasts, and convening conferences in a manner that enhances inclusion and collaboration between industry, university and governmental members of the ATS, large pharma and biotech sectors.
▪ Continue the annual BEAR Cage competition seeking mechanisms of program growth, increased visibility, and further engagement from senior leaders within the Society to support the next generation of ATS scientists and leaders.
▪ Continue efforts at publication in the AJRCCM, Research News Quarterly or ATS Scholar highlighting innovative advancements in therapeutics, devices, and other public health/policy issues relevant to the ATS community, with ties to the fundamental goals of the Bear Cage and in support of the RIS.
▪ Continue collaboration with the Steering Committee on Advancement and Learning (SCALe) and others to identify novel opportunities for junior members, ensuring that engagement evolves to create greater knowledge and awareness of innovation, entrepreneurship, and translational sciences as well as career opportunities in industry.
▪ Collaborate with the Pulmonary Function Testing Committee to develop and implement plan for engagement.
▪ The committee will consider a new initiative in conjunction with either the Health Equity and Diversity Committee or the Environmental Health Policy Committee.
o If a partnership is pursued with the Health Equity and Diversity Committee, the focus would be on creating a multi-stakeholder working group that decides upon a roadmap with 2-3 actionable items that have the potential to palpably improve enrollment of a diverse population into pulmonary fibrosis research trials.
o The second initiative would aim to explore how to move the needle with reference to particulate matter exposure and associated impact on respiratory health +/- exploring if environmental impacts can/should be routinely included/studied in respiratory clinical trials.
▪ The committee will be responsible for reviewing content it has previously posted to the ATS website to determine if it should be updated and moved to the new site or archived/deleted. Using parameters established by the ATS Digital Content Committee as a guideline, committee members will make necessary modifications to ensure the content is accurate and conforms with established ATS standards. Reviews are to be completed by December 1, 2024.
